Dr. Philippe Monteyne MD, PhD is an operating partner at Innesto Partners. 

Philippe is Senior Advisor for Life Sciences at AltamarCam Partners, and Partner of their Life Sciences VC Aliath Bioventures in Barcelona. AltamarCAM is a leading investment manager in private markets with more than 21 billion euros in assets committed by investors.

Philippe Monteyne has extensive and highly successful experience as a life sciences investor and pharmaceutical professional. Before joining Aliath and AltamarCam, Philippe has been a Senior Partner of the private equity fund Fund+ in Belgium, having contributed to multiple investments including very profitable ones.

Philippe Monteyne is a Neurologist and holds a PhD in viral immunology from the Catholic University of Louvain and a postdoctoral degree in neuroimmunology from the Pasteur Institute in Paris.

Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.

Amongst his achievements, was the development and launch of GSK's Cervical Cancer Vaccine, Cervarix, the R&D work that allowed to develop Strimvelis and Tegsedi (gene therapy and oligonucleotide in rare diseases).

He also served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"), of the Bioaster Insitute in Lyon, and of the « Fondation Plan Alzheimer France ».

He is a Board Director of several Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), and is part-time Professor and course coordinator of an Advanced Master in Biotech & MedTech Ventures at Solvay Management School, Brussels.